ONO-7913 Phase I study (ONO-7913)

An open-label, uncontrolled, dose escalation study in patients with advanced or metastatic solid cancers (ONO-7913-01)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225170

Enrollment

Registered

2020-04-20

Start date

2020-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Interventions

investigational material(s) Generic name etc : Magrolimab(ONO-7913) INN of investigational material : Magrolimab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with histologically or cytologically confirmed advanced or metastatic solid tumors 2.ECOG Performance Status of 0-1 3.Patients with life expectancy of at least 3 months

Exclusion criteria

Exclusion criteria: 1. Patients with multiple cancers 2. Patients with history of serious allergy

Design outcomes

Primary

Measure	Time frame
safety Safety, tolerability	—

Secondary

Measure	Time frame
pharmacokinetics Pharmacokinetics	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026